The invention provides compositions and methods for further reducing IOP in a subject who has already achieved maximal IOP reduction using known IOP lowering agents. The activity of an ocular hypotensive treatment regimen may be increased by adding an S1P antagonist to prevent S1P mediated reversal as a result of decreased aqueous humor outflow.
申请公布号
WO2012135095(A2)
申请公布日期
2012.10.04
申请号
WO2012US30523
申请日期
2012.03.26
申请人
ALLERGAN, INC.;WOODWARD, DAVID F.;HEIDELBAUGH, TODD M.;STAMER, W. DANIEL
发明人
WOODWARD, DAVID F.;HEIDELBAUGH, TODD M.;STAMER, W. DANIEL